AstraZeneca’s efzimfotase alfa wins FDA priority review for hypophosphatasia treatment in patients aged 2+

• AstraZeneca’s Alexion unit won FDA Priority Review for efzimfotase alfa to treat hypophosphatasia in patients aged 2 and older.
• The FDA action date is expected in the first half of 2027 under the PDUFA timeline.
• The filing is backed by Phase III results from the HICKORY, MULBERRY, and CHESTNUT trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on September 18, 2026, and is solely responsible for the information contained therein.